Special Issue

Treatment of Peripheral Vascular Disease - Present and Future

Message from the Guest Editors

At present, cardiovascular disease still takes the highest death toll worldwide. Peripheral artery disease (PAD) patients suffer from a particularly poor prognosis. With this knowledge, efforts to reduce ischemic events and improve cardiovascular outcomes have been the driving force behind cardiovascular research in recent decades. One central strategy to improve cardiovascular outcomes is lipid lowering. For the time being, the most important drugs to reduce cholesterol still are statins. Next to statins. PCSK-9 inhibitors have already shown their benefit in PAD. Alternatively, nonstatin lipid-lowering therapy, i.e ezetimibe or bempedoic acid has yet to prove its value beyond combination. Another important field in the treatment of peripheral arterial disease is by influencing platelet aggregation and coagulation. This remains of great importance especially before, during and after vascular intervention or surgery. Finally, anticoagulation management especially in secondary prophylaxis of deep vein thrombosis and pulmonary embolism is a challenging task, especially in situations with the rare thrombophilic predisposition.

Guest Editors

Dr. Jörn F Dopheide

- 1. Department of Medicine I, Jena University Hospital, Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany
- 2. Bern University Hospital, University of Bern, 3010 Bern, Switzerland
- 3. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), 6800 Feldkirch, Austria

Prof. Dr. Heinz Drexel

 Department for Internal Medicine, Hospital Bregenz, Bregenz, Austria
 Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria

Deadline for manuscript submissions

closed (27 December 2023)



Journal of Clinical <u>Medici</u>ne

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/134378

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).